Global BioAccess Fund — Full Portfolio

Acesion Pharma is a biotech company developing pharmaceutical treatments.

BiotechHealthtechMedical DevicesCopenhagen, DK

Ulrik Sørensen(COO & Co-founder)Morten Grunnet(CSO & Co-founder)Anders Gaarsdal Holst(CEO & CMO)Torgeir Vaage(CFO)in

Co-investorsAlpha Wave GlobalCanaan PartnersNovo HoldingsBroadview Ventures

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

Raj Kannan(Executive Officer, Director)

BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Co-investorsAndera PartnersAvego BioScience CapitalJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)inAnsu Satpathy(Founder)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)Howard Chang(Co-founder)in

Co-investors8VCAndreessen HorowitzArtis VenturesHAWKTAILPfizer Venture InvestmentsWing+6 more

BiotechMorris Plains, US

Emily Weng(Executive Officer)Bittoo Kanwar(Executive Officer)James Andrew Whitney(Executive Officer)Neena Bitritto-Garg(Executive Officer, Director, Promoter)Matthew McKevitt(Executive Officer)

Ensho is a biopharmaceutical company developing NSHO-101, an oral, selective small molecule α4β7 inhibitor intended as a once-daily treatment for patients with inflammatory bowel disease (IBD).

BiotechHealthtechMorris Plains, US

Neena Bitritto-Garg(Founder)inGerhard Hagn(Chief Executive Officer)Danielle Fry(Chief Operating Officer and Chief Legal Officer)Tory Trippe(Vice President, Head of Finance and Corporate Development)Matthew R. Warr(Senior Vice President, Research & Head of Biology)Andy Whitney(Chief Scientific Officer)

Co-investorsAvego BioScience Capital

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health FundAlbionVCEpidarex CapitalNovartis Venture FundUCL Technology FundBioGeneration Ventures

Nuvig Therapeutics develops immune-modulating medicines for autoimmune diseases by harnessing endogenous regulatory mechanisms to resolve immune dysregulation.

BiotechHealthtechMedical Devices

Pamela Conley(Founder)in

Co-investorsB Capital GroupB4 CapitalMission BiocapitalSanofi VenturesDigitalis VenturesNorwest Venture Partners

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)

Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGreatPoint VenturesJeito Capital+6 more

ShiraTronics is a medical device company developing an implantable device to treat chronic migraine disease.

BiotechHardwareHealthtechMedical DevicesBrooklyn Park, US

Robert Binney(Executive Officer, Director)

BoardJoyce Erony(Director)inZack Scott(Director)Brad Vale(Director)inCasey Tansey(Director)Mudit Jain(Executive Officer, Director)

Co-investorsAmzak HealthAPERTURE Venture PartnersBreakout VenturesNorwest Venture PartnersOSF VenturesSeroba Life Sciences+3 more

Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types.

BiotechDeep TechMedical Devices

Co-investorsBioAdvanceAgent Capital